Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Photodynamic Therapy, Luminol Used to Kill Cancer cells

By Biotechdaily staff writers
Posted on 02 Aug 2006
Forcing cancer cells to light up could activate light-sensitive drugs that are then able to kill them without damaging nearby healthy tissue, according to recent research.

Researchers based at the College of Judea and Samaria (Ariel) and in association with Bar-Ilan University (Ramat Gan), both in Israel, have for the first time combined two novel techniques to target cancer cells. More...
The first is a form of photodynamic therapy, which delivers a light-sensitive drug specifically to cancer cells. The second technique uses a compound called luminol to generate light inside individual cells, activating the drug and killing the cell. The scientists reported their findings in the July 18, 2006, edition of the British Journal of Cancer.

Photodynamic therapy exploits the properties of specific chemicals that are triggered by normal visible light. In photodynamic therapy, laser light is shone from outside the body to activate chemotherapy drugs. Now it may be possible to use luminol to produce light inside cells, reducing side effects, and enabling the therapy to be used to treat a wider range of tumors.

Lead researcher Dr. Michael Firer, of the department of chemical engineering and Biotechnology at the College of Judea and Samaria, said, "The two big problems with photodynamic therapy are getting the light-sensitive drug to only target cancer cells, and delivering light to the drug to activate it once it is in the right place. We've uniquely combined two cutting-edge technologies to direct a drug to cancer cells and to generate a light source inside the cells. This stops the drug from killing healthy cells. It also means that we might be able to use photodynamic therapy to treat tumors deep inside the body that external light sources cannot reach. We've shown it works in the lab--if it works in real life, we'll have an exciting new way to treat cancer.”

Another unexpected and positive result of using targeted photodynamic therapy was that it removed the drug resistance that develops when untargeted therapies are employed.

Prof. John Toy, medical director of Cancer Research UK, which owns the British Journal of Cancer, remarked, "These are promising results, although there is a long way to go before we can know if this will work in patients. If it does work, it could become a safe, non-invasive option for treating many types of cancers.”



Related Links:
College of Judea and Samaria
Bar-Ilan University

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Rapid Molecular Testing Device
FlashDetect Flash10
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.